How Cancer Therapies Trigger Senescence That Fuels Treatment Resistance
Chemotherapy and radiotherapy cause tumor microenvironment cells to age, creating a resistance-promoting environment. New targets may break this cycle.
Resumen
Standard cancer treatments like chemotherapy and radiotherapy don't just kill tumor cells — they also trigger senescence in surrounding microenvironment cells, including endothelial cells, immune cells, and fibroblasts. These aged cells release inflammatory signals via the senescence-associated secretory phenotype (SASP), which paradoxically makes tumors more aggressive and resistant to further treatment. This review from Tongji Hospital researchers maps the mechanisms behind therapy-induced senescence across both tumor and non-tumor cells, and evaluates emerging strategies — including senolytics and senomorphics — that could be combined with conventional treatments to overcome resistance and improve outcomes.
Resumen detallado
Cancer treatment resistance remains one of the greatest barriers to long-term survival, and the tumor microenvironment (TME) plays a central role in enabling it. This 2026 review in Drug Resistance Updates investigates a previously underappreciated mechanism: how chemotherapy and radiotherapy induce senescence not only in tumor cells but across the broader cellular ecosystem of the TME.
Conventional antitumor therapies trigger senescence primarily through DNA damage and oxidative stress. While initially intended to halt cancer cell proliferation, this process also activates the senescence-associated secretory phenotype (SASP) — a cocktail of pro-inflammatory cytokines, growth factors, and proteases that can paradoxically promote tumor malignancy and immune evasion.
The review's key contribution is its emphasis on non-tumoral components. Endothelial cells, cancer-associated fibroblasts, and immune cells within the TME also undergo therapy-induced senescence. When these stromal and immune populations senesce, they remodel the microenvironment in ways that shelter remaining tumor cells, suppress anti-tumor immunity, and create physical and biochemical barriers to drug delivery — all fueling resistance.
The authors survey current therapeutic strategies aimed at disrupting this cycle, including senolytics (agents that selectively eliminate senescent cells) and senomorphics (agents that suppress SASP without killing senescent cells). Combining these approaches with standard chemo- or radiotherapy could potentially convert a resistance-promoting environment into one that enhances treatment efficacy.
Importantly, this review is based on existing literature rather than new experimental data, meaning conclusions are interpretive syntheses. The field also lacks robust clinical trial data on senescence-targeted combination therapies, and the context-dependent roles of SASP — sometimes tumor-suppressive — add complexity to therapeutic targeting.
Hallazgos clave
- Chemotherapy and radiotherapy induce senescence in tumor microenvironment cells, not just tumor cells themselves.
- Senescent endothelial cells, fibroblasts, and immune cells remodel the TME to promote treatment resistance via SASP.
- SASP-driven inflammatory signaling creates a pro-tumorigenic environment that shields cancer cells from further therapy.
- Senolytics and senomorphics are emerging combination strategies to neutralize therapy-induced microenvironmental senescence.
- Targeting TME senescence alongside conventional therapy may overcome a key driver of clinical treatment failure.
Metodología
This is a narrative review synthesizing published literature on therapy-induced senescence in the tumor microenvironment. No original experimental data were generated. The authors drew from mechanistic studies and preclinical evidence to construct a framework linking TME senescence to treatment resistance.
Limitaciones del estudio
As a review, this paper does not present new clinical or experimental data, limiting the strength of causal conclusions. SASP has context-dependent effects — sometimes suppressing tumors — making blanket targeting strategies risky without better patient stratification. Clinical evidence for senescence-targeted combination therapies in humans remains sparse.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: